Home / Guides / Zepbound vs. Wegovy
Two brands. Different strengths.
Zepbound vs. Wegovy: more weight loss, or a lower price and more approved uses?
By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD · Updated
Zepbound led to more weight loss in SURMOUNT-5 (2025); Wegovy costs less at most doses, $349 a month self-pay (checked Nov. 12, 2026). Zepbound is $299 to $449 by dose; $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699. Compounded tirzepatide, which isn’t FDA-approved or Zepbound, is $115 a month at NexLife on the 12-month plan, or $129 month to month.
- Approved uses: Zepbound adds sleep apnea; Wegovy adds heart, liver, teens
- Forms: Zepbound pens or vials; Wegovy pens or a daily pill
- Medicare Bridge: $50 a month for Wegovy or the Zepbound KwikPen

$115/mo on a 12-month plan, all-inclusive, same price at every dose
Or $129/mo month to month
Brand-name Zepbound: $299 to $449 a month at LillyDirect, by dose; $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699
About 3 minutes of health questions · No insurance needed · Not prescribed? No charge for medication
See all 4 plans and what a year costs
| Plan | Per month | 12 months at this rate |
|---|---|---|
| 12-month Most savings | $115 | $1,380 |
| 6-month | $119 | $1,428 |
| 3-month | $125 | $1,500 |
| Month to month | $129 | $1,548 |
Month to month costs $168 more over 12 months than the 12-month plan. Plans renew until you cancel. Month to month is billed monthly; the 3-, 6- and 12-month plans are paid upfront, in full, at checkout ($375, $714 or $1,380).
Price Match Guarantee†. Paying less elsewhere? We match your regular monthly price. How it works
4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 1, 2026)LegitScript-certified
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. The vial shown is an illustration. Always use the strength on your pharmacy’s label.
- Licensed U.S. providers
- LegitScript certified
- Free expedited shipping
- HSA, FSA, Affirm, Klarna, Afterpay
- 24/7 support, real people
- Filled by Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA)
Compounded tirzepatide isn’t FDA-approved, isn’t Zepbound and wasn’t studied in Zepbound’s or Wegovy’s trials. A licensed provider prescribes it only when it offers a significant difference for you.
At a glance
Zepbound or Wegovy? 6 quick answers on results, uses and cost
Zepbound and Wegovy in six questions. Each one is explained below.
| Question | Answer |
|---|---|
| More weight loss? | Zepbound, on average: 20.2% vs. 13.7% over 72 weeks in SURMOUNT-5 (NEJM, 2025), the head-to-head trial. |
| Approved for more? | Wegovy: heart risk, the liver disease MASH and teens 12 and older. Zepbound adds sleep apnea in adults with obesity. |
| Lower self-pay price? | Wegovy at most doses: its pen is $349 a month. Zepbound is $299 to $449 by dose; $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699. |
| A pill? | Only Wegovy: a daily pill at $149 to $299 a month. There’s no Zepbound pill. |
| Medicare Part D? | The $50 Bridge covers Wegovy’s pen and pill but only Zepbound’s KwikPen, through December 31, 2027. |
| Side effects? | The same kinds, mostly nausea, diarrhea, vomiting and constipation. Each label’s rates come from its own trials. |
Trial results are for FDA-approved Zepbound and Wegovy; compounded tirzepatide wasn’t studied. Prices checked November 1, 2026.
- Tell us about you About 3 minutes of health questions
- A licensed provider decides You’re prescribed only if it’s right for you
- Your partner pharmacy ships Usually within 1 to 2 business days, free
Key takeaways
- Zepbound led to more weight loss: 20.2% vs. 13.7% on average over 72 weeks in SURMOUNT-5 (NEJM, 2025).
- Wegovy is approved for more: heart risk, the liver disease MASH and teens; Zepbound adds sleep apnea.
- Wegovy costs less at most doses: the pen is $349 a month self-pay (checked Nov. 12, 2026).
- Zepbound is $299 to $449 a month; its $449 from 7.5 mg needs a refill within 45 days, or it’s $499 to $699.
- Coverage: CVS Caremark added Zepbound back October 1, 2026; Medicare’s $50 Bridge covers Wegovy’s pen and pill but only Zepbound’s KwikPen.
- At NexLife, compounded tirzepatide is $115 a month on the 12-month plan at every dose. It isn’t FDA-approved or Zepbound.
At a glance
What’s the difference between Zepbound and Wegovy?
Both are FDA-approved weight-loss medicines you can take as a weekly shot, and Wegovy also comes as a daily pill. They differ in the medicine inside, what else they’re approved for and what they cost.
| Zepbound | Wegovy | |
|---|---|---|
| Made by | Eli Lilly | Novo Nordisk |
| The medicine | Tirzepatide, which acts on two hormone receptors, GIP and | Semaglutide, which acts on one, |
| FDA-approved forfrom each label | Weight reduction in adults with obesity, or overweight with a weight-related condition. Moderate to severe obstructive sleep apnea in adults with obesity | Weight reduction in adults (pen or pill), and in children 12 and older with obesity (pen). Lowering the risk of heart attack, stroke or cardiovascular death in adults with heart disease and obesity or overweight (pen or pill). MASH with moderate to advanced liver scarring (pen) |
| How you take it | A weekly shot: a KwikPen or multi-dose vial (4 doses each), a single-dose pen or a single-dose vial | A weekly shot from a pen, or a pill once a day |
| Dose rangefrom each label | 2.5 mg to 15 mg a week | Pen: 0.25 mg to 2.4 mg a week, or 7.2 mg as Wegovy HD. Pill: 1.5 mg to 25 mg a day |
| Main weight trialtrial and year | 20.2% average loss SURMOUNT-5 (NEJM, 2025), 72 weeks, head to head | 13.7% average loss SURMOUNT-5, the same trial. Wegovy HD: 18.7% in STEP UP (2025), a separate trial |
| Other outcome trialsin the labels | Sleep apnea: in SURMOUNT-OSA (NEJM, 2024), two 52-week studies, the apnea-hypopnea index fell by 25.3 and 29.3 events an hour on Zepbound, vs. 5.3 and 5.5 on placebo | Heart: in SELECT (NEJM, 2023), 6.5% had a heart attack, stroke or cardiovascular death on Wegovy vs. 8% on placebo |
| Common side effectslabel %, vs. placebo | Nausea 25% to 29% (8%), diarrhea 19% to 23% (8%), vomiting 8% to 13% (2%), constipation 11% to 17% (5%), on 5 to 15 mg | Nausea 44% (16%), diarrhea 30% (16%), vomiting 24% (6%), constipation 24% (11%), on 2.4 mg |
| Self-pay price, a monthchecked November 1, 2026 | $299 at 2.5 mg, $399 at 5 mg and $449 from 7.5 mg at LillyDirect; the $449 needs a refill within 45 days, or it’s $499 to $699 | Pen $349, or $399 for Wegovy HD; pill $149 to $299 (NovoCare). $199 for each of a new patient’s first two fills through December 31, 2026 |
| Insurance and Medicare, 2026 to 2027 | Lilly’s savings cards end December 31, 2026. Medicare’s Bridge: $50, KwikPen only. A Part D plan should cover | Savings card: as little as $25. List price falls to $675 on January 1, 2027. Medicare’s Bridge: $50, pen or pill |
Swipe the table sideways to see every column.
From the Zepbound (revised August 2026) and Wegovy (revised June 2026) labels, Lilly’s SURMOUNT-5 release, Novo Nordisk’s STEP UP announcement, LillyDirect, NovoCare and Medicare.gov, checked November 1, 2026. Side-effect rates come from each drug’s own placebo trials, not one shared trial. A Zepbound month is 28 days; a Wegovy pen month is 4 pens.
Head to head
Is Zepbound or Wegovy better for weight loss?
On average, Zepbound. In SURMOUNT-5 (NEJM, 2025), the trial that compared the two directly, people lost more weight on Zepbound than on Wegovy.
| What it compared | Zepbound and Wegovy, each at the highest dose a person tolerated: 10 or 15 mg of Zepbound, 1.7 or 2.4 mg of Wegovy |
|---|---|
| Who took part | 751 adults with obesity, or overweight with high blood pressure, high cholesterol, sleep apnea or heart disease. No one had diabetes |
| Where and how long | Sites across the U.S. and Puerto Rico, for 72 weeks. It wasn’t blinded: people knew which shot they took |
| Average weight lost | 20.2% on Zepbound, 13.7% on Wegovy 50.3 lb vs. 33.1 lb, counting everyone who started (Lilly) |
| Lost a quarter of their weight or more | 31.6% on Zepbound, 16.1% on Wegovy |
| Published | The New England Journal of Medicine, May 11, 2025. Eli Lilly sponsored the trial |
From Lilly’s SURMOUNT-5 release (December 4, 2024) and Weill Cornell Medicine’s summary of the published trial, read November 1, 2026. These results are for FDA-approved Zepbound and Wegovy.
What it didn’t test. Wegovy HD, the 7.2 mg dose the FDA approved on March 19, 2026, wasn’t in it, and neither was the Wegovy pill. In its own trial, STEP UP, 7.2 mg averaged 18.7% at 72 weeks, against 15.6% on 2.4 mg and 3.9% on placebo (Novo Nordisk, January 17, 2025). That’s a separate trial with different people, so it can’t say how Wegovy HD compares with Zepbound.
Who it leaves out. No one in SURMOUNT-5 had diabetes, so it can’t say how the two compare for people who do.
How the two molecules work, and the trials behind each: tirzepatide vs. semaglutide.
Approved uses
What are Zepbound and Wegovy approved for?
Both treat excess weight. Beyond that, Zepbound is approved for sleep apnea, and Wegovy for heart risk, a liver disease called MASH, and teens.
Sleep apnea: Zepbound
Approved for moderate to severe obstructive sleep apnea in adults with obesity, at 10 or 15 mg a week. In SURMOUNT-OSA (NEJM, 2024), two 52-week studies in its label, the apnea-hypopnea index fell by 25.3 and 29.3 events an hour, against 5.3 and 5.5 on placebo.
Heart risk: Wegovy
Approved to lower the risk of heart attack, stroke or cardiovascular death in adults with heart disease and obesity or overweight. In SELECT (NEJM, 2023), with 17,604 adults, 6.5% had one of those events on Wegovy and 8% on placebo.
Liver disease: Wegovy
The pen is approved for MASH, a fatty liver disease, with moderate to advanced scarring and no cirrhosis. It’s an accelerated approval, based on improvement in MASH and liver scarring.
Teens: Wegovy
The pen is approved for weight reduction in children 12 and older with obesity. Zepbound and the Wegovy pill are for adults only.
Both are for long-term weight reduction, alongside a reduced-calorie diet and more activity. Neither label recommends combining it with another
When each use was approved. Zepbound for weight on November 8, 2023, and for sleep apnea on December 20, 2024, Lilly says. Wegovy for heart risk on March 8, 2024, the FDA says, and for MASH on August 15, 2025, Novo Nordisk says. The Wegovy pill joined its label in December 2025, its change list shows, and Wegovy HD, the 7.2 mg pen, was approved on March 19, 2026, the FDA says.
In their words
What do the FDA and Zepbound’s label say about Zepbound and Wegovy?
Two lines behind this page: Wegovy’s newest dose, and why you take one or the other, not both.
SURMOUNT-5 compared Zepbound with Wegovy up to 2.4 mg; the FDA has since approved a higher Wegovy dose:
“The U.S. Food and Drug Administration today approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection, called Wegovy HD, for weight loss and long-term maintenance of weight loss for certain adult patients.”
U.S. Food and Drug Administration, FDA approves fourth product under National Priority Voucher program, higher dose semaglutide, March 19, 2026
Both labels advise against combining GLP-1 medicines, so if you switch, your provider tells you when to stop one and start the other:
“Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, Limitations of Use (revised August 2026)
Which fits you
Zepbound or Wegovy: which is right for you?
It depends on your health, your coverage and how you want to take it. Here’s where each one fits.
If you want the most weight loss
In SURMOUNT-5 (NEJM, 2025), the head-to-head trial, people lost more weight on Zepbound than on Wegovy, on average. Your health, your coverage and how you respond matter as much.
If you have sleep apnea
Zepbound is the one approved for it. With Medicare, a Part D plan “should cover
GLP-1 medications” for moderate to severe sleep apnea, Medicare.gov says.If you have heart disease
Wegovy, as a pen or a pill, is approved to lower the risk of heart attack and stroke in adults with heart disease and excess weight. Zepbound isn’t approved for that. Tirzepatide’s diabetes brand, Mounjaro, is approved for that in adults with type 2 diabetes at high risk.
If needles are the problem
Wegovy comes as a daily pill. There’s no Zepbound pill: Lilly’s daily pill is Foundayo, a different medicine.
If your coverage ends January 1, 2027
Check your plan’s 2027 drug list first. Lilly’s savings cards and Wegovy’s $199 price for each of a new patient’s first two fills end December 31, 2026. What changes in 2027.
If cost is the barrier
Self-pay, the Wegovy pill is $149 to $299 a month, the pen $349 and Zepbound $299 to $449 by dose; its $449 from 7.5 mg needs a refill within 45 days, or it’s $499 to $699. Compounded tirzepatide, which isn’t FDA-approved, is $115 a month at NexLife on the 12-month plan, or $129 month to month.
Your provider decides. A licensed provider weighs your health history, other conditions and medicines before prescribing either one.
These trials studied FDA-approved Zepbound and Wegovy; compounded tirzepatide wasn’t studied. NexLife’s providers prescribe compounded tirzepatide for weight loss. It isn’t a treatment for type 2 diabetes and doesn’t replace Mounjaro or your diabetes care.
Step by step
How do you choose between Zepbound and Wegovy?
It depends on your health, your coverage and how you want to take it; here’s how to weigh each.
- Weigh the head-to-head result. In SURMOUNT-5 (NEJM, 2025), adults without diabetes lost 20.2% on average on Zepbound and 13.7% on Wegovy over 72 weeks. It didn’t test Wegovy HD or the Wegovy pill, and compounded tirzepatide wasn’t studied.
- Match the approved uses to your health. Zepbound is also approved for moderate to severe sleep apnea in adults with obesity. Wegovy is approved to lower heart risk in adults with heart disease and excess weight, and its pen for MASH and teens 12 and older.
- Pick a shot or a pill. Zepbound is a weekly shot only: a KwikPen, a single-dose pen or a vial. Wegovy is a weekly shot or a daily pill, taken in the morning on an empty stomach.
- Compare side effects. Both cause the same kinds of side effects, mostly nausea, diarrhea, vomiting and constipation. In separate trials, 25% to 29% on Zepbound had nausea (8% on placebo) and 44% on Wegovy 2.4 mg (16% on placebo).
- Compare self-pay prices. Wegovy pen: $199 for each of a new patient’s first two fills (through Dec. 31, 2026), then $349, or $399 for Wegovy HD. Zepbound: $299 to $449 by dose; its $449 from 7.5 mg needs a refill within 45 days, or it’s $499 to $699.
- Check your coverage. Your plan’s 2027 drug list decides; Lilly’s savings cards and Wegovy’s $199 price for each of a new patient’s first two fills end December 31, 2026. Medicare’s $50 Bridge covers Wegovy’s pen and pill but only Zepbound’s KwikPen, if you qualify.
Prices checked November 1, 2026; your provider decides which one, if either, fits you.
How you take it
How do you take Zepbound and Wegovy? Pens, vials and a pill
Both start low and step up, at least 4 weeks per step. Zepbound is a weekly shot only; Wegovy is a weekly shot or a daily pill.
| Zepbound | Wegovy pen | Wegovy pill | |
|---|---|---|---|
| How often | Once a week | Once a week | Once a day |
| First dosefrom the label | 2.5 mg for 4 weeks, to start only | 0.25 mg for 4 weeks | 1.5 mg for 30 days |
| Steps up | By 2.5 mg, after at least 4 weeks on each dose | 0.5 mg, 1 mg, then 1.7 mg, 4 weeks each | 4 mg, then 9 mg, 30 days each |
| Usual maintenance | 5, 10 or 15 mg for weight; 10 or 15 mg for sleep apnea | 1.7 or 2.4 mg, from week 17. Up to 7.2 mg (Wegovy HD) after 4 weeks on 2.4 mg, if more weight loss is needed | 25 mg, from day 91 |
| Highest dose | 15 mg a week | 7.2 mg a week | 25 mg a day |
| Forms | KwikPen or multi-dose vial, 4 doses each; single-dose pen; single-dose vial (vials need needles and syringes, bought separately) | Single-dose pens (4 a month, including the 7.2 mg Wegovy HD pen) or syringes; a FlexTouch pen holds four 2.4 mg doses | 30-tablet bottles of 1.5, 4, 9 or 25 mg |
| How to take it | Under the skin once a week. The day can change if doses stay at least 3 days apart. Never share a KwikPen | Under the skin once a week | In the morning on an empty stomach, with up to 4 ounces of plain water. Wait at least 30 minutes before eating, drinking or other pills |
| A missed dosewhat the label says | Take it within 4 days. After that, skip it and take the next one on your usual day | Take it if the next dose is more than 2 days away; if not, skip it. After 2 or more missed doses in a row, restart the dose steps at a lower dose (section 2.4, read Nov. 12, 2026). Call your provider first | Skip it and take the next pill the following day |
Swipe the table sideways to see every column.
The schedules in each label (Zepbound revised August 2026, Wegovy June 2026), read November 1, 2026. They describe the label, not a plan for you: your provider decides your dose and when it changes.
Side effects
Zepbound vs. Wegovy side effects: how do they compare?
They’re the same kinds, mostly nausea, diarrhea, vomiting and constipation. Each label reports its own trials, so the rates below aren’t a direct comparison.
| Side effect | Zepbound 5 to 15 mg | Placebo | Wegovy 2.4 mg | Placebo |
|---|---|---|---|---|
| Nausea | 25% to 29% | 8% | 44% | 16% |
| Diarrhea | 19% to 23% | 8% | 30% | 16% |
| Vomiting | 8% to 13% | 2% | 24% | 6% |
| Constipation | 11% to 17% | 5% | 24% | 11% |
| Abdominal pain | 9% to 10% | 5% | 20% | 10% |
| Indigestiondyspepsia | 9% to 10% | 4% | 9% | 3% |
| Fatigue | 5% to 7% | 3% | 11% | 5% |
| Dizziness | 4% to 5% | 2% | 8% | 4% |
| Stopped because of side effects | 4.8% to 6.7% | 3.4% | 6.8% | 3.2% |
Swipe the table sideways to see every column.
Not head-to-head: each column comes from that drug’s own placebo-controlled weight trials, as its label reports them (Zepbound Table 1, revised August 2026; Wegovy, revised June 2026), read November 1, 2026. These figures are for the FDA-approved brands.
In SURMOUNT-5 (NEJM, 2025), which did compare them, the most common side effects on both were gastrointestinal and generally mild to moderate, Lilly said.
Wegovy HD. At 7.2 mg, 22% had dysesthesia, a change in skin sensation, against 6% on 2.4 mg, the label says. Nausea (39% vs. 35%) and vomiting (22% vs. 16%) were also more common.
Birth control and pregnancy. Zepbound can make birth control pills work less well: its label advises a non-oral method, or adding a barrier method, for 4 weeks after you start and after each dose increase. Zepbound’s label says to stop it when a pregnancy is recognized; Wegovy’s says to stop at least 2 months before a planned pregnancy.
What helps with the stomach side effects: tirzepatide side effects.
Cost
What do Zepbound and Wegovy cost? Every way to pay
Self-pay, Wegovy costs less at most doses: $349 a month for the pen against $449 for Zepbound from 7.5 mg with a refill within 45 days, otherwise $499 at 7.5 mg and $699 at 10 to 15 mg (checked Nov. 12, 2026). With coverage, each maker’s savings card can bring either to as little as $25.
| How you pay | What you pay | Good to know |
|---|---|---|
| Zepbound, LillyDirectself-pay; KwikPen or vials | $299 at 2.5 mg, $399 at 5 mg, $449 from 7.5 mg to 15 mg | Refill within 45 days, or 7.5 mg is $499 and 10 to 15 mg $699. A month is 28 days |
| Wegovy pen, NovoCareself-pay | $349 at 0.25 mg to 2.4 mg; $399 for Wegovy HD 7.2 mg | $199 for each of a new patient’s first two fills through December 31, 2026 (0.25 or 0.5 mg; the prescription must be written and received by then) |
| Wegovy pill, NovoCareself-pay; 30 tablets | $149 at 1.5 mg, $199 at 4 mg, $299 at 9 or 25 mg | No new-patient offer listed |
| TrumpRx.govself-pay listings | Zepbound vials from $299; Wegovy pen $199 for each of a new patient’s first two fills through December 31, 2026, then $349; Wegovy pill from $149 | Zepbound vial orders go through LillyDirect. Wegovy’s is a pharmacy coupon that can’t count toward a deductible |
| Commercial insurancewith each maker’s savings card | As little as $25, if your plan covers it | Lilly’s cards end December 31, 2026. Each card takes up to $100 off a month. Government plans can’t use them |
| Medicare | $50 a month | Wegovy pen or pill, or the Zepbound KwikPen only, with prior authorization, through December 31, 2027 |
| Compounded tirzepatide online25 programs in our price index | $126 to $599 a month, all in (median $285, checked Nov. 4, 2026) | Not FDA-approved and not Zepbound. Checked November 1, 2026. Already paying less for it elsewhere? We match it: Price Match Guarantee† |
| NexLife,compounded tirzepatide | $115 a month on the 12-month plan $129 month to month | Not FDA-approved. The same price at every dose, with no membership fee |
NexLife Price Match Guarantee†. Already on compounded tirzepatide or semaglutide with another licensed provider, and paying less? We match your regular monthly price. How it works
Swipe the table sideways to see every column.
Self-pay prices from LillyDirect, wegovy.com, NovoCare’s terms and TrumpRx.gov, and the Bridge from Medicare.gov, all checked November 1, 2026: the medication alone, with the prescriber’s visit extra. Compounded prices are all in, month to month, from our
A year adds up. Thirteen four-week fills of Zepbound come to $5,187 at 5 mg, and $5,837 from 7.5 mg if each refill comes within 45 days. Thirteen fills of the Wegovy pen at $349 come to $4,537, and 12 bottles of the pill at the 25 mg maintenance dose to $3,588. A year of compounded tirzepatide at NexLife, which isn’t FDA-approved and isn’t Zepbound, is $1,380 on the 12-month plan or $1,548 month to month.
The prices move differently. Zepbound’s rises with the dose, from $299 to $449 a month; the $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699. The Wegovy pen is $349 at every dose from 0.25 mg to 2.4 mg, and Wegovy HD $399.
Coverage
Does insurance cover Zepbound or Wegovy in 2026 and 2027?
Your plan’s drug list decides, and a big one moved twice. CVS Caremark preferred Wegovy from July 2025, then added Zepbound back on October 1, 2026. Medicare covers them for weight loss only through its $50 Bridge.
CVS Caremark prefers Wegovy and removes Zepbound from its commercial template formularies. CVS said it would “take a formulary action to prefer Wegovy and remove Zepbound.”
The Medicare
GLP-1 Bridge starts: $50 a month for Wegovy, Foundayo or the Zepbound KwikPen, for people with Part D who qualify.Zepbound returns to CVS Caremark’s template lists “as an additional preferred option.” Employers that use them can still customize them.
Lilly’s Zepbound savings cards end, their terms say. So does Wegovy’s $199 price for each of a new patient’s first two fills.
Wegovy’s list price falls from $1,349.02 to $675 a month, which can lower what you pay in coinsurance or before your deductible is met. Novo says the cut doesn’t affect self-pay prices; NovoCare’s Wegovy page says, under self-pay, “Pricing to be updated after December 31, 2026.” Medicare’s negotiated semaglutide price, $274 for a 30-day supply, also starts: that’s what Medicare pays, not your copay.
The Bridge is set to end. Its prior authorization covers refills and dose changes until then, but not a switch to another
GLP-1.
From CVS Health (June 27, 2025, and May 28, 2026), Medicare.gov, CMS, Lilly’s and Novo Nordisk’s terms, NovoCare’s Wegovy savings page and Novo’s February 24, 2026 announcement, read November 1, 2026.
Who qualifies for the Bridge. Adults with Part D and a BMI of 35 or more; or 30 or more with heart failure with preserved ejection fraction, uncontrolled high blood pressure or stage 3a or worse kidney disease; or 27 or more with prediabetes, a past heart attack or stroke, or symptomatic peripheral artery disease. Not people with type 2 diabetes, moderate to severe sleep apnea or fatty liver disease: their Medicare drug plan “should cover
Employer plans in 2027 are each setting their own lists:
Switching
Can you switch from Wegovy to Zepbound?
Yes, with a new prescription. There’s no label conversion between them, so your provider decides your starting dose.
Get a new prescription
Each is its own medicine. Neither label gives a dose conversion between them, so your provider decides where you start and how fast you step up.
Don’t overlap them
Zepbound’s label advises against using it with any other
GLP-1 medicine, and Wegovy’s says the same of other semaglutide products andGLP-1s. Your provider tells you when to stop one and start the other.Check the form your coverage pays for
Medicare’s Bridge pays for the Zepbound KwikPen, not single-dose pens or vials. A switch of
GLP-1 needs a new prior authorization there.Expect to start low again
Both start at a low dose and step up. Wegovy’s label says the steps lower the risk of stomach side effects, and Zepbound’s 2.5 mg first dose is for starting only.
The timing and the cost of a move from semaglutide, brand-name or compounded, to tirzepatide: semaglutide to tirzepatide.
Compounded
Compounded tirzepatide vs. Wegovy: what’s the difference?
They’re different medicines, and only one is FDA-approved. Compounded tirzepatide isn’t Zepbound or Wegovy, and it wasn’t studied in their trials.
“This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.”
A different medicine from Wegovy
Compounded tirzepatide is tirzepatide; Wegovy is semaglutide. It also isn’t Zepbound: a state-licensed 503A pharmacy prepares it for one patient’s prescription.
Not FDA-approved
The FDA doesn’t review compounded drugs for safety, effectiveness or quality before they’re sold, and a compounded drug isn’t a generic.
Not studied in these trials
SURMOUNT-5 used FDA-approved Zepbound and Wegovy. No one knows from that trial how a compounded version compares.
Usually cheaper
Compounded tirzepatide runs $126 to $599 a month online in our price index, all in, month to month (median $285, checked Nov. 4, 2026), against $349 for a self-pay Wegovy pen and $299 to $449 for Zepbound, by dose (its $449 from 7.5 mg needs a refill within 45 days, or it’s $499 to $699). Paying less elsewhere? Price Match Guarantee†
These trials studied FDA-approved Zepbound and Wegovy; compounded tirzepatide wasn’t studied. A licensed provider prescribes compounded tirzepatide only when it offers a significant difference for you. More: compounded vs. brand-name tirzepatide.
At NexLife
Compounded tirzepatide at NexLife: what you get and what it costs
Compounded tirzepatide is $115 a month on the 12-month plan, or $129 month to month. The price is the same at every dose, and a licensed provider decides if it’s right for you.
| 12-month plan | $115 a month |
|---|---|
| 6-month plan | $119 a month |
| 3-month plan | $125 a month |
| Month to month | $129 a month |
The same price at every dose, from your first dose to your highest, with no membership fee. Month to month, $129 is $156 under the $285 median of the 25 tirzepatide programs in our
Included: a licensed provider who follows your dose, the medication, a nutrition plan, a 1:1 coaching call, free expedited shipping and real people 24/7 at
Who fills it: Absolute Pharmacy in Lutz, FL, or Boudreaux’s New Drug Store in Lake Charles, LA, both state-licensed 503A partner pharmacies. Questions about your order come to us, not the pharmacy.
What happens next: a 3-minute online assessment, then a licensed provider reviews it and prescribes only if treatment is right for you. Not prescribed? No charge for medication. Your partner pharmacy usually ships within 1 to 2 business days.
Ways to pay: HSA or FSA cards (NexLife provides a letter of medical necessity), or Affirm, Klarna or Afterpay at checkout. People with Medicare can pay for themselves.
Paying less elsewhere? If you already take compounded tirzepatide or semaglutide through another licensed U.S. telehealth provider or clinic, send a receipt from the last 60 days and we match your regular monthly price. Price Match Guarantee†
NexLife’s providers prescribe compounded tirzepatide for weight loss. It isn’t a treatment for type 2 diabetes and doesn’t replace Mounjaro or your diabetes care.
Safety
What do the Zepbound and Wegovy labels warn about?
Both carry the same boxed warning about thyroid tumors, and most of the same serious warnings.
The boxed warning, for both
In rodents, both caused thyroid C-cell tumors; whether they do in people isn’t known. Don’t use either if you or a family member has had medullary thyroid carcinoma (MTC), or if you have MEN 2.
Who shouldn’t take them
Anyone with that thyroid history, or who has had a serious allergic reaction to the medicine. Don’t combine either with another
GLP-1 medicine.Serious side effects in both labels
Pancreatitis, gallbladder problems, low blood sugar with diabetes medicines, kidney injury from dehydration, severe stomach problems, serious allergic reactions, eye problems in type 2 diabetes, and food or liquid entering the lungs under anesthesia. Wegovy’s also lists a faster heart rate.
When to call
Stop and call your provider right away for severe stomach pain that won’t go away. Get help at once for signs of a serious allergic reaction. Tell your provider about gallbladder symptoms or vomiting or diarrhea that won’t stop, and tell every provider before surgery.
Questions about a side effect? Call or text
Vial math
How many units is your semaglutide dose?
It depends on your vial’s strength. Here are the Wegovy label’s dose steps at two example strengths.
| Weeks | Weekly dose | At 2.5 mg/mL | At 5 mg/mL |
|---|---|---|---|
| 1 to 4 | 0.25 mg | 0.1 mL (10 units) | 0.05 mL (5 units) |
| 5 to 8 | 0.5 mg | 0.2 mL (20 units) | 0.1 mL (10 units) |
| 9 to 12 | 1 mg | 0.4 mL (40 units) | 0.2 mL (20 units) |
| 13 to 16 | 1.7 mg | 0.68 mL (68 units) | 0.34 mL (34 units) |
| 17 onward | 2.4 mg | 0.96 mL (96 units) | 0.48 mL (48 units) |
The math: mL = dose ÷ strength (mg per mL); units = mL × 100. At 2.5 mg/mL, 1 mg is 1 ÷ 2.5 = 0.4 mL, or 40 units. At 5 mg/mL, the same 1 mg is 0.2 mL, or 20 units.
Both strengths are examples only. The same dose is a different number of units at a different strength, so read the strength on your own vial’s label. Your prescription sets your dose and schedule, which may differ from these label steps. Every step: the semaglutide dosage chart. Or enter your own vial’s strength in the semaglutide dosage calculator.
What does NexLife cost?
One flat price at every dose.
No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†
GIP + 12-month plan $115/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan; $129/mo month to month.
Check my eligibilityCompounded, not FDA-approved · Not prescribed? No charge for medication

12-month plan $95/mo
Semaglutide
Weekly
Compounded, not FDA-approved · Not prescribed? No charge for medication
Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms
The NexLife Price Match Guarantee†
Paying less elsewhere?
Keep your price. Upgrade your care.
Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.
Zepbound vs. Wegovy: your questions
Fair questions about NexLife
- Will my price go up with my dose?
- No. You pay the same at every dose.
- What if I’m not prescribed?
- You aren’t charged for medication.
- Can I cancel?
- Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
- Do I need insurance?
- No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.
Is Zepbound or Wegovy cheaper without insurance?
Wegovy, at most doses. Self-pay, the Wegovy pen is $349 a month at NovoCare ($399 for Wegovy HD) and the pill $149 to $299. Zepbound is $299 to $449 at LillyDirect, by dose; $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699 (checked November 1, 2026). A month of either pen is 28 days.
Is compounded tirzepatide cheaper than Wegovy?
Usually. Compounded tirzepatide runs $126 to $599 a month in our
Does the Medicare GLP-1 Bridge cover both Zepbound and Wegovy?
Yes, with limits. From July 1, 2026 to December 31, 2027, people with Part D who qualify pay $50 a month for the Wegovy pen or pill, or the Zepbound KwikPen. The Bridge doesn’t cover single-dose Zepbound vials or pens, and it needs prior authorization (Medicare.gov, checked Nov. 12, 2026).
Does CVS Caremark cover Zepbound or Wegovy?
Zepbound is back on its main commercial lists. CVS Caremark preferred Wegovy and dropped Zepbound on July 1, 2025, then brought Zepbound back “as an additional preferred option” on October 1, 2026 (CVS Health, May 28, 2026). Employers can customize those lists, so check your plan’s 2027 drug list.
Is there a Zepbound pill like the Wegovy pill?
No. Zepbound comes only as a weekly shot: a KwikPen, a single-dose pen or a vial. Lilly’s daily pill for obesity is Foundayo (orforglipron), a different medicine the FDA approved on April 1, 2026. The Wegovy pill is semaglutide, taken once a day on an empty stomach.
Can I switch from Wegovy to Zepbound?
Yes, with a new prescription. Neither label gives a dose conversion between them, so your provider decides where you start and how fast you step up. Don’t overlap them: both labels advise against combining them with another
Can you take Zepbound and Wegovy together?
No. Zepbound’s label advises against using it with any other
Does Zepbound lower heart risk like Wegovy does?
Not on its label. Wegovy is approved to lower the risk of heart attack, stroke or cardiovascular death in adults with heart disease and obesity or overweight. Zepbound’s uses are weight reduction and sleep apnea. Tirzepatide’s diabetes brand, Mounjaro, is approved to lower that risk in adults with type 2 diabetes at high risk (label revised August 2026).
Which has more side effects, Zepbound or Wegovy?
Their labels list the same kinds, mostly stomach-related, from separate trials. In Wegovy’s, 44% on 2.4 mg had nausea (16% on placebo); in Zepbound’s, 25% to 29% did (8% on placebo). About 7% stopped because of side effects on either: 6.8% on Wegovy 2.4 mg and 6.7% on Zepbound 15 mg.
Which is better, Zepbound or Wegovy?
Zepbound led to more weight loss; Wegovy is approved for more and costs less self-pay at most doses. In SURMOUNT-5 (NEJM, 2025), adults without diabetes lost 20.2% on average on Zepbound and 13.7% on Wegovy over 72 weeks. Wegovy adds heart risk, MASH and teens; its pen is $349 a month (checked November 1, 2026).
Is Wegovy HD better than Zepbound?
SURMOUNT-5 can’t say: Wegovy HD, the 7.2 mg dose the FDA approved on March 19, 2026, wasn’t in it. In its own trial, STEP UP, 7.2 mg averaged 18.7% at 72 weeks, but that’s a separate trial with different people, so it can’t say how Wegovy HD compares with Zepbound.
Can I switch from Zepbound to Wegovy?
Yes, with a new prescription. Neither label gives a dose conversion between them, so your provider decides where you start and how fast you step up, and tells you when to stop one and start the other. CVS Caremark preferred Wegovy from July 2025, then added Zepbound back on October 1, 2026.
Which is better for sleep apnea, Zepbound or Wegovy?
Zepbound. It’s approved for moderate to severe obstructive sleep apnea in adults with obesity, at 10 or 15 mg a week, and Wegovy isn’t. With Medicare, a Part D plan “should cover GLP-1 medications” for moderate to severe sleep apnea, Medicare.gov says.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare eye condition that can cause sudden vision loss in one eye; call your provider right away if that happens (FDA). Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other
Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at
† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.
Who wrote and medically reviewed this page?
Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.
Labels, makers’ prices, TrumpRx.gov, Medicare and CVS Health checked November 1, 2026.
- How we checked. Every fact here comes from the Zepbound, Wegovy and Mounjaro labels, Lilly’s and Novo Nordisk’s releases and price pages, the FDA, TrumpRx.gov, Medicare.gov, CMS and CVS Health, read on November 1, 2026. Compounded prices come from our
GLP-1 price index, checked November 1, 2026. Trial results carry the trial’s name and year, and we list announced changes only. Zepbound, Mounjaro, KwikPen and Foundayo are trademarks of Eli Lilly and Company; Wegovy, Ozempic and Rybelsus of Novo Nordisk. NexLife isn’t affiliated with either. - Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email hello@nexlife.us and we’ll fix it.
- How we work. How we review programs · GLP-1 price index · Is NexLife legit? · States NexLife serves
Paying less elsewhere? We match it.†
You know the trade-offs. Next: a 3-minute check.
A licensed provider reviews your health history and decides if compounded tirzepatide is right for you: $115 a month on the 12-month plan, or $129 month to month, at every dose.
4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 1, 2026) · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified
Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.
- 1Tell us about you
Start online with your health history.
- 2A licensed provider decides
Online, following your state’s rules. You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.
Sources
- Zepbound (tirzepatide) prescribing information, Eli Lilly, revised August 2026. Read November 1, 2026.
- Zepbound Medication Guide, Eli Lilly, revised August 2026. Read November 1, 2026.
- Mounjaro (tirzepatide) prescribing information, Eli Lilly, revised August 2026 (the heart-risk indication). Read November 1, 2026.
- Wegovy (semaglutide) prescribing information, Novo Nordisk, revised June 2026. Read November 1, 2026.
- Wegovy prescribing information, the FDA’s copy of the June 2026 revision (section 14.1, SELECT). Read November 1, 2026; section 2.4 (missed doses) read Nov. 12, 2026.
- Eli Lilly: FDA approves Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (December 20, 2024). Read November 1, 2026.
- FDA: first treatment to reduce the risk of serious heart problems specifically in adults with obesity or overweight, Wegovy (March 8, 2024). Read November 1, 2026.
- Novo Nordisk: Wegovy approved in the US for the treatment of MASH (August 15, 2025). Read November 1, 2026.
- FDA: approval of Wegovy HD, higher-dose semaglutide (March 19, 2026). Read November 1, 2026.
- Eli Lilly: Zepbound superior to Wegovy in head-to-head trial, SURMOUNT-5 (December 4, 2024). Read November 1, 2026.
- Weill Cornell Medicine: Head-to-head trial compares weight loss drugs (May 12, 2025). Read November 1, 2026.
- The New England Journal of Medicine: Tirzepatide as compared with semaglutide for the treatment of obesity, SURMOUNT-5 (May 11, 2025). The published trial.
- ACC.org: SURMOUNT-OSA, N Engl J Med 2024;391:1193-205. For the trial’s year, read November 1, 2026.
- Cleveland Clinic: SELECT, published in The New England Journal of Medicine (November 11, 2023). For the trial’s year, read November 1, 2026.
- Novo Nordisk: Semaglutide 7.2 mg in the STEP UP obesity trial (January 17, 2025). Read November 1, 2026.
- Eli Lilly: FDA approves Foundayo (orforglipron) (April 1, 2026). Read November 1, 2026.
- LillyDirect: Zepbound self-pay prices. Checked Nov. 12, 2026.
- Eli Lilly: Zepbound savings and self-pay terms. Read Nov. 12, 2026.
- Novo Nordisk: What to pay for Wegovy. Checked November 1, 2026.
- NovoCare Pharmacy: terms and self-pay prices. Read Nov. 12, 2026.
- NovoCare: Wegovy savings offer and self-pay pricing. Checked November 1, 2026.
- TrumpRx.gov:
GLP-1 listings. Checked November 1, 2026. - TrumpRx.gov: Zepbound vial. Checked November 1, 2026.
- TrumpRx.gov: Wegovy pen. Checked November 1, 2026.
- TrumpRx.gov: Wegovy pill. Checked November 1, 2026.
- Medicare.gov: Weight loss drugs (the Medicare
GLP-1 Bridge). Read Nov. 12, 2026. - CMS: Medicare
GLP-1 Bridge. Read Nov. 12, 2026. - CMS: Medicare drug price negotiation, negotiated prices for 2027 (fact sheet). Read November 1, 2026.
- Novo Nordisk: US list price reduction for Wegovy, Ozempic and Rybelsus (February 24, 2026). Read November 1, 2026.
- CVS Health: Improving access and affordability to high-cost weight management drugs (June 27, 2025). Read November 1, 2026.
- CVS Health: CVS Caremark expands
GLP-1 weight management coverage options (May 28, 2026). Read November 1, 2026. - FDA: Compounding and the FDA, questions and answers. Read November 1, 2026.
- NexLife:
GLP-1 price index. Compounded prices checked November 1, 2026. - NexLife: pricing, every plan.